The content on this site is intended for healthcare professionals only
Dr Shu-Qiang Yuan speaks to ecancer about the NEOSUMMIT-01 trial.
The NEOSUMMIT-01 trial shows that adding the PD-1 antibody toripalimab to perioperative chemotherapy significantly improves survival in patients with locally advanced, resectable gastric or gastroesophageal junction cancer.
He says that after 3 years, event-free survival was 74.7% with toripalimab plus chemotherapy versus 56.2% with chemotherapy alone (HR 0.52, P=0.047), and overall survival was 81.3% versus 72.2% (HR 0.45, P=0.031).
These results highlight toripalimab combined with chemotherapy as a promising perioperative strategy for improving long-term outcomes in this patient population.
Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer
FFX/bevacizumab plus atezolizumab improves PFS in first-line dMMR/MSI-H mCRC
Adjuvant pembrolizumab fails to improve recurrence-free survival after curative therapy in hepatocellular carcinoma
Physical activity reduces fatigue and improves quality of life in colorectal cancer survivors
Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer
MS-553 shows promise in treating chronic lymphocytic leukaemia
Zanzalintinib plus atezolizumab improves survival in refractory mCRC
Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC
Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers
